Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the clinical-stage biopharmaceutical company, is heading into its most consequential period since flotation, as interim data from its lead drug candidate POLB 001 approaches and a second trial prepares to start.
POLB 001 is designed as an oral preventative therapy for cytokine release syndrome (CRS), a potentially life-threatening inflammatory reaction that affects more than 70% of patients receiving CAR T-cell and bispecific antibody cancer treatments.
The TOPICAL study (Trial of Prevention of ImmunoCytokine Adverse events in Myeloma), being conducted at leading haematology centres including The Christie, The Royal Marsden, and University College London Hospitals, is expected to generate interim data this summer.
Both Cavendish and Shore Capital, which act as brokers to the company, are clear that this readout is the defining near-term catalyst.
Shore describes POLB 001 as potentially the first oral therapy for both prevention and treatment of CRS, arguing it could remove a commercial bottleneck by enabling cancer immunotherapies to be administered in community hospital settings rather than specialist units.
That is not a niche opportunity: Cavendish cites a total addressable market of above $10 billion in relapsed or refractory multiple myeloma and diffuse large B-cell lymphoma alone.
At the same time, the label expansion of Johnson & Johnson's Tecvayli (teclistamab) from fifth-line to second-line therapy in March 2026 has materially widened the potential patient population.
Poolbeg noted in Tuesday's release that it is progressing partnering discussions with several companies, with engagement increasing as data approaches, a detail Shore flags as significant.
The second programme, an oral GLP-1 receptor agonist developed with AnaBio Technologies targeting obesity and diabetes, is expected to begin a proof-of-concept study in the second half of 2026, recruiting up to 20 patients.
Cavendish maintains its 'buy' rating with a 19p target price, implying upside of more than 300% to the current 4.6p.